Zydus Lifesciences Limited (ZYDUSLIFE) share price and analysis
ZYDUSLIFE last traded at ₹1,204.20 (+1.02%) on the NSE. Market cap ₹1,20,119 Cr (Large cap), Pharma & Healthcare sector.
Overall rating: 6.6/10 (Good)
- Valuation: 6.4/10
- Profitability: 6.1/10
- Growth: 5.0/10
- Financial health: 6.3/10
- Price trend: 9.0/10
Long-term view: Good for long-term. More strengths than weaknesses for a multi-year hold. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.
Strengths of ZYDUSLIFE
- Long-term trend (+14.6% vs 200-DMA): Trading well above its 200-day average, a clear long-term uptrend.
- Revenue growth (YoY) (+29.2%): Sales are growing fast.
- 50-DMA vs 200-DMA (+10.6% gap): 50-day average is above the 200-day (golden-cross setup), so medium-term momentum is up.
- Valuation (P/E) (P/E 28.8 vs sector 41.1): Slightly cheaper than sector peers on earnings.
- Debt / equity (0.46): Comfortable debt level.
- Net profit margin (13.8%): Healthy profit margins.
- 6-month performance vs Nifty 50 (+19.0% vs +7.4%): Outperforming the Nifty 50.
- 52-week range (5% below high): Trading near its 52-week high, so buyers are in control.
- Momentum (RSI 14) (RSI 56): Mildly positive momentum.
- Volatility (1Y) (24% annualised): Below-average volatility.
Weaknesses of ZYDUSLIFE
- Profit growth (YoY) (-25.8%): Profits are falling sharply.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 28.8 | Cheaper than peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 24.4 | Profits expected to grow | below today's P/E (28.8) and near 41 |
| Price / book | 4.32 | Normal | 2–6 |
| EPS (TTM) | ₹41.85 | Profitable | above ₹0 |
| Return on equity | 14.7% | Average | 15%+ (below 10% is weak) |
| Debt / equity | 0.46 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 13.8% | Healthy | 10%+ (below 5% is thin) |
| Operating margin | 17.2% | Average | 20%+ strong, below 10% thin |
| Revenue growth | +29.2% | Growing well | 10%+ a year (below 3% is weak) |
| Profit growth | -25.8% | Falling | 10%+ a year (falling is weak) |
| Dividend yield | 0.08% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 1.02 | Adequate | 1.5+ (below 1 is tight) |
| 52W high | ₹1,266.60 | 5% below · near the high | price in the top 40% of its 52-week range |
| 52W low | ₹835.50 | Price is 44% above it | |
| 50-DMA | ₹1,161.40 | Price 3.7% above | price above it = short-term uptrend |
| 200-DMA | ₹1,050.36 | Price 14.6% above | price above it = long-term uptrend |
| 1Y return | +27.0% | Beat the Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.31 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 75.2% | Owners have a big stake | 50%+ shows owner commitment |
| Institutions | 16.2% | Moderate interest | 30%+ is strong |
| Analyst target | ₹1,233.12 | 2.4% upside · 29 analysts | 8%+ upside |
Questions about ZYDUSLIFE
What is the share price of Zydus Lifesciences Limited (ZYDUSLIFE) today?
ZYDUSLIFE last traded at ₹1,204.20 (+1.02% on the day) on the NSE. Its 52-week range is ₹835.50 to ₹1,266.60. Prices are delayed and come from Yahoo Finance.
Is ZYDUSLIFE a good stock for the long term?
StockLens rates ZYDUSLIFE 6.6 out of 10 (Good) overall. Its long-term verdict is "Good for long-term": More strengths than weaknesses for a multi-year hold. Strengths: uptrend, revenue growth, bullish moving averages. Concerns: falling profits.
Is ZYDUSLIFE share overvalued?
ZYDUSLIFE trades at a P/E of 28.8 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Cheaper than peers". Its price-to-book ratio is 4.32.
Is ZYDUSLIFE good for short-term trading?
The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 14.6% above its 200-day average and 14-day RSI is 56.
Which stocks are similar to ZYDUSLIFE?
Similar Pharma & Healthcare stocks of comparable size include Dr. Reddy's Laboratories, Apollo Hospitals, Laurus Labs, Cipla, Aurobindo Pharma. You can compare up to 4 of them side by side on StockLens.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products. It also provides biological products in the areas of oncology, autoimmune disorders, nephrology, inflammation, rheumatology, hepatology, and infectious diseases; and designs and executes clinical trials across new chemical entities (NCEs), biologics, vaccines, and specialty generics. In addition, the company operates seasonal, skin and healthcare, and food and nutrition products under the Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and RiteBite Max Protein brands. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.
Stocks similar to ZYDUSLIFE
- Dr. Reddy's Laboratories share price
- Apollo Hospitals share price
- Laurus Labs share price
- Cipla share price
- Aurobindo Pharma share price
- Max Healthcare share price
Compare ZYDUSLIFE with DRREDDY, APOLLOHOSP, LAURUSLABS
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.